Lupus Erythematosus, Systemic Clinical Trial
Official title:
Physical Therapy for Improvement of Quality of Life in Patients With Systemic Lupus Erythematosus (SLE)
The purpose of this study is to see if there is an improvement in patient's quality of life, pain, and fatigue after undergoing a supervised exercise program. If improvement is found, this will help guide standard of care with lupus patients with a focus on exercise for improvement of endurance, pain and overall health.
After patients have been selected and consented for this study, they will fill out a series
of questionnaires. These surveys are used to stratify the patient's disease activity, assess
perception of disease limitations including quality of life, fatigue and pain. We intend to
use the Systemic Lupus Disease Activity Index (SLEDAI) to quantify disease activity and the
SLICC to characterize the study population.
Pain, fatigue and depression will be assessed with the Pain Visual analogue scale, Fatigue
Severity Score (FSS), Patient Global Assessment and BECK depression scale. Other initial
data to be collected include patient's prednisone dose and resting heart rate. No specific
laboratory data will be collected for this study. Patients will continue with standard of
care monitoring based on their disease activity and medications.
The 100 patients will be randomized approximately 50 in the exercise group and 50 in the
relaxation therapy group. The relaxation group will serve as the control arm of the study.
The patients in the relaxation therapy group will then undergo a training session on
biofeedback as well as receive further materials on relaxation techniques and a relaxation
tape. The relaxation tape will request subjects to systematically contract and relax eleven
isolated muscle groups. These muscle groups include; hands and wrists, biceps and triceps,
shoulders alone, neck, tongue and mouth, eyes, nose and forehead, back alone, abdominal area
alone, thighs alone, calves and feet and finally toes alone. This group of subjects will be
asked to perform relaxation exercises at home a minimum of three times a week.
The subjects in the exercise group will have visits about 2 times per week for a total of 8
weeks, for a total of 16 visits. The first visit will include a general evaluation
(strength, range of motion, standing balance, gait assessment, baseline vitals),
determination of heart rate range for exercise and explanation of exercise portion of the
study and home exercise program. Visits 2 through 16 you will participate in simple,
supervised exercise at the physical therapy center at the University of Chicago. Heart rates
will be measured several times throughout your exercise visits. Additionally, subjects will
be asked to rate your level of pain, your blood pressure will be taken before and after and
you will be advised regarding at home exercises.
Each subject will be seen for 16 visits total, unless a he/she stops attending PT sessions
on their own.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Recruiting |
NCT05967520 -
JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus
|
Phase 2 | |
Completed |
NCT02875691 -
Effect of Green Tea on Treatment of Lupus
|
Phase 2 | |
Completed |
NCT02922114 -
Comparison of the Clinical Examination and the Joint Ultrasonography in Lupus Patients
|
N/A | |
Withdrawn |
NCT01702038 -
Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE
|
Phase 2 | |
Terminated |
NCT00368264 -
TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )
|
Phase 2/Phase 3 | |
Completed |
NCT00094380 -
Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
|
Phase 1/Phase 2 | |
Completed |
NCT00065806 -
Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)
|
Phase 3 | |
Completed |
NCT00005436 -
Lupus Cohort--Thrombotic Events and Coronary Artery Disease
|
N/A | |
Recruiting |
NCT03543839 -
Trial of Belimumab in Early Lupus
|
Phase 4 | |
Completed |
NCT03098823 -
A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE
|
Phase 4 | |
Recruiting |
NCT05899907 -
Efficacy and Safety of Telitacicept in Early SLE
|
Phase 4 | |
Completed |
NCT04956484 -
Belimumab In Early Systemic Lupus Erythematosus
|
Phase 4 | |
Completed |
NCT05326841 -
Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythematosus Patients .
|
Phase 3 | |
Completed |
NCT02655640 -
The Impact of Illness Perceptions on Health Related Outcomes in Patients With Lupus and Systemic Sclerosis
|
N/A | |
Completed |
NCT02034344 -
A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
|
Phase 0 | |
Terminated |
NCT00089804 -
Study of LJP 394 in Lupus Patients With History of Renal Disease
|
Phase 3 | |
Completed |
NCT00071487 -
Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)
|
Phase 2 | |
Completed |
NCT02349061 -
A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
|
Phase 2 | |
Recruiting |
NCT05636670 -
Assessment of Cognitive Function and Gut Microbiota Analysis in Real World Patients With Lupus Cerebrovascular Disease
|